Dyslipidemia – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 7 PAGES: 204

Dyslipidemia - Pipeline Review, H1 2012', provides an overview of the Dyslipidemia therapeutic pipeline. This report provides information on the therapeutic development for Dyslipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dyslipidemia. 'Dyslipidemia - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

More Info
									                        Dyslipidemia – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1741IDB
                                                                                           Publication Date: February 2012




Dyslipidemia – Pipeline Review, H1 2012                                                    GMDHC1741IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Dyslipidemia – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ............................................................................................................................................................................... 11
    List of Figures .............................................................................................................................................................................. 13
Introduction....................................................................................................................................................................................... 14
    Global Markets Direct Report Coverage ...................................................................................................................................... 14
Dyslipidemia Overview ..................................................................................................................................................................... 15
Therapeutics Development............................................................................................................................................................... 16
    An Overview of Pipeline Products for Dyslipidemia ..................................................................................................................... 16
Dyslipidemia Therapeutics under Development by Companies ....................................................................................................... 18
Dyslipidemia Therapeutics under Investigation by Universities/Institutes ......................................................................................... 23
Late Stage Products ......................................................................................................................................................................... 25
    Comparative Analysis .................................................................................................................................................................. 25
Mid Clinical Stage Products.............................................................................................................................................................. 26
    Comparative Analysis .................................................................................................................................................................. 26
Early Clinical Stage Products ........................................................................................................................................................... 27
    Comparative Analysis .................................................................................................................................................................. 27
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 28
    Comparative Analysis .................................................................................................................................................................. 28
Dyslipidemia Therapeutics – Products under Development by Companies ..................................................................................... 29
Dyslipidemia Therapeutics – Products under Investigation by Universities/Institutes....................................................................... 31
Companies Involved in Dyslipidemia Therapeutics Development .................................................................................................... 32
    Bristol-Myers Squibb Company ................................................................................................................................................... 32
    F. Hoffmann-La Roche Ltd. ......................................................................................................................................................... 33
    Shionogi & Co., Ltd...................................................................................................................................................................... 34
    Eli Lilly and Company .................................................................................................................................................................. 35
    GlaxoSmithKline plc .................................................................................................................................................................... 36
    VIRxSYS Corporation .................................................................................................................................................................. 37
    Merck & Co., Inc. ......................................................................................................................................................................... 38
    Euroscreen S.A. .......................................................................................................................................................................... 39
    Neptune Technologies & Bioressources Inc. ............................................................................................................................... 40
    Biocon Limited ............................................................................................................................................................................. 41
    Dr. Reddy's Laboratories Limited................................................................................................................................................. 42
    Japan Tobacco Inc. ..................................................................................................................................................................... 43
    Kowa Company, Ltd. ................................................................................................................................................................... 44
    Mitsubishi Tanabe Pharma Corporation ...................................................................................................................................... 45
    Pfizer Inc...................................................................................................................................................................................... 46
    Zydus Cadila Healthcare Limited ................................................................................................................................................. 47
    AlbireoPharma ............................................................................................................................................................................. 48
    Amarin Corporation plc ................................................................................................................................................................ 49
    Genfit ........................................................................................................................................................................................... 50
    Karo Bio....................................................................................................................................................................................... 51
    Ligand Pharmaceuticals Incorporated ......................................................................................................................................... 52



Dyslipidemia – Pipeline Review, H1 2012                                                                                                      GMDHC1741IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                     Page(2)
Dyslipidemia – Pipeline Review, H1 2012




    LifeCycle Pharma A/S ................................................................................................................................................................. 53
    Cardiome Pharma Corp ............................................................................................................................................................... 54
    IPCA Laboratories Limited ........................................................................................................................................................... 55
    Choongwae Pharma Corp ........................................................................................................................................................... 56
    Resverlogix Corp. ........................................................................................................................................................................ 57
    Pronova BioPharma ASA ............................................................................................................................................................ 58
    Intas Pharmaceuticals Ltd. .......................................................................................................................................................... 59
    Jenrin Discovery, Inc. .................................................................................................................................................................. 60
    Metabolex, Inc ............................................................................................................................................................................. 61
    Spherix Incorporated ................................................................................................................................................................... 62
    Ache Laboratorios Farmaceuticos S/A ........................................................................................................................................ 63
    Arisaph Pharmaceuticals, Inc. ..................................................................................................................................................... 64
    Ferrer Internacional S.A. ............................................................................................................................................................. 65
    aRigen Pharmaceuticals, Inc. ...................................................................................................................................................... 66
    Quatrx Pharmaceutical Company ................................................................................................................................................ 67
    Cerenis Therapeutics SA............................................................................................................................................................. 68
    VIA Pharmaceuticals, Inc. ........................................................................................................................................................... 69
    Essentialis, Inc............................................................................................................................................................................. 70
    Limerick BioPharma, Inc.............................................................................................................................................................. 71
    KYORIN Pharmaceutical Co., Ltd................................................................................................................................................ 72
    Esperion Therapeutics, Inc. ......................................................................................................................................................... 73
    Connexios Life Sciences Pvt. Ltd. ............................................................................................................................................... 74
    PHARMENA SA .......................................................................................................................................................................... 75
Dyslipidemia – Therapeutics Assessment ........................................................................................................................................ 76
    Assessment by Monotherapy Products ....................................................................................................................................... 76
    Assessment by Combination Products ........................................................................................................................................ 77
    Assessment by Route of Administration ...................................................................................................................................... 78
    Assessment by Molecule Type .................................................................................................................................................... 80
Drug Profiles..................................................................................................................................................................................... 82
    MK-0524A - Drug Profile ............................................................................................................................................................. 82
        Product Description................................................................................................................................................................. 82
        Mechanism of Action ............................................................................................................................................................... 82
        R&D Progress ......................................................................................................................................................................... 82
    MK-0524B - Drug Profile ............................................................................................................................................................. 84
        Product Description................................................................................................................................................................. 84
        Mechanism of Action ............................................................................................................................................................... 84
        R&D Progress ......................................................................................................................................................................... 84
    KB2115 - Drug Profile.................................................................................................................................................................. 86
        Product Description................................................................................................................................................................. 86
        Mechanism of Action ............................................................................................................................................................... 86
        R&D Progress ......................................................................................................................................................................... 86
    AMR101 - Drug Profile ................................................................................................................................................................ 87
        Product Description................................................................................................................................................................. 87
        Mechanism of Action ............................................................................................................................................................... 87


Dyslipidemia – Pipeline Review, H1 2012                                                                                                   GMDHC1741IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Dyslipidemia – Pipeline Review, H1 2012




        R&D Progress ......................................................................................................................................................................... 87
    LCP-Feno - Drug Profile .............................................................................................................................................................. 89
        Product Description................................................................................................................................................................. 89
        Mechanism of Action ............................................................................................................................................................... 89
        R&D Progress ......................................................................................................................................................................... 89
    JTT705 - Drug Profile .................................................................................................................................................................. 90
        Product Description................................................................................................................................................................. 90
        Mechanism of Action ............................................................................................................................................................... 90
        R&D Progress ......................................................................................................................................................................... 90
    GSK256073 - Drug Profile ........................................................................................................................................................... 92
        Product Description................................................................................................................................................................. 92
        Mechanism of Action ............................................................................................................................................................... 92
        R&D Progress ......................................................................................................................................................................... 92
    GED-aPC - Drug Profile .............................................................................................................................................................. 93
        Product Description................................................................................................................................................................. 93
        Mechanism of Action ............................................................................................................................................................... 93
        R&D Progress ......................................................................................................................................................................... 93
    TA-8995 - Drug Profile ................................................................................................................................................................. 94
        Product Description................................................................................................................................................................. 94
        Mechanism of Action ............................................................................................................................................................... 94
        R&D Progress ......................................................................................................................................................................... 94
    MP-136 - Drug Profile .................................................................................................................................................................. 95
        Product Description................................................................................................................................................................. 95
        Mechanism of Action ............................................................................................................................................................... 95
        R&D Progress ......................................................................................................................................................................... 95
    MBX-8025 - Drug Profile ............................................................................................................................................................. 96
        Product Description................................................................................................................................................................. 96
        Mechanism of Action ............................................................................................................................................................... 96
        R&D Progress ......................................................................................................................................................................... 96
    GFT505 - Drug Profile ................................................................................................................................................................. 97
        Product Description................................................................................................................................................................. 97
        Mechanism of Action ............................................................................................................................................................... 97
        R&D Progress ......................................................................................................................................................................... 97
    DGAT-1 - Drug Profile ................................................................................................................................................................. 99
        Product Description................................................................................................................................................................. 99
        Mechanism of Action ............................................................................................................................................................... 99
        R&D Progress ......................................................................................................................................................................... 99
    VIA-3196 - Drug Profile ............................................................................................................................................................. 100
        Product Description............................................................................................................................................................... 100
        Mechanism of Action ............................................................................................................................................................. 100
        R&D Progress ....................................................................................................................................................................... 100
    DRL 17822 - Drug Profile .......................................................................................................................................................... 101
        Product Description...........................................................................................
								
To top